Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 10, 2007, Pages 1635-1645

  Czepczyński, Rafał ^a   Parisella, Maria Gemma ^b   Kosowicz, Jerzy ^a   Mikołajczak, Renata ^c   Ziemnicka, Katarzyna ^a   Gryczyńska, Maria ^a   Sowiński, Jerzy ^a   Signore, Alberto ^b,d  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Medullary thyroid carcinoma; Peptide receptor scintigraphy; Somatostatin analogues

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; EDDA HYNIC OCTREOTATE TC 99M; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SUCCIMER TC 99M; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; ECHOGRAPHY; FALSE POSITIVE RESULT; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MEDULLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 34748865440     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0479-1     Document Type: Article

References (43)

1. Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005;89:122-9.
2. Shoback D, Marcus R, Bikle D, Strewler G. Medullary thyroid carcinoma. In: Greenspan FS, Gardner DG, editors. Basic & clinical endocrinology. 6th ed. New York: Lange Medical Books/McGraw-Hill; 2001.
3. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol 2003;4:339-47.
4. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070-5.
5. Schlumberger M, Pacini F. Medullary thyroid carcinoma. In: Schlumberger M, Pacini F, editors. Thyroid tumors. 2nd ed. Editions Nucleon, Paris; 2003.
6. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-34.
7. Saller B, Moeller L, Gorges R, Janssen OE, Mann K. Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 2002;110:403-7.
8. Wang Q, Takashima S, Fukuda H, Takayama F, Kobayashi S, Sone S. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2002;125:842-8.
9. Moll L, McEwan AJ. Iodine 131 MIBG scintigraphy of neuroendocrine tumours other than phaeochromocytoma and neuroblastoma. J Nucl Med 1987;28:978-88.
10. 99mTc(V)-dimercaptosuccinic acid (DMSA). Henry Ford Hosp Med J 1989;37:167-8.
11. 131iodine MIBG in the imaging of medullary thyroid carcinoma. J Nucl Med 1986;27:1150-3.
12. Behr TM, Gratz S, Markus PM, Dunn RM, Hufner M, Schauer A, et al. Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997;80:2436-57.
13. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
14. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912-6.
15. 1-octreotide. Eur J Nucl Med 2000;27:628-37.
16. DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AH, Wolfe HJ. Calcitonin and carcinoembryogenic antigen as tumour markers in medullary thyroid carcinoma. Am J Clin Pathol 1978;70:587-94.
17. Dörr U, Frank-Raue K, Raue F, Hehrmann R, Iser G, Bihl H. Localisation of recurrences from medullary thyroid carcinoma by somatostatin-receptor scintigraphy [abstract]. Eur J Nucl Med 1993;20:843.
18. 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59(5):565-73.
19. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277-83.
20. Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995;42:31-7.
21. 99mTc(V)DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 2001;26:683-8.
22. 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318-25.
23. 111In-DTPAoctreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003;44:708-16.
24. 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur J Nucl Med Mol Imaging 2003;30:1402-6.
25. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-33.
26. 3]- octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742-53.
27. 111In-DOTA-tate. Eur J Nucl Med Mol Imaging 2006;33:831-40.
28. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm 2004;19:211-7.
29. Ohta H, Yamamoto K, Endo K. A new imaging agent for medullary thyroid cancer. J Nucl Med 1984;25:23-5.
30. 99mTc(V) DMSA in the diagnostic value of MTC. Henry Ford Hosp Med J 1989;37:175-7.
31. Guerra UP, Pizzocara C, Terzi A. New tracers for imaging MTC. Nucl Med Commun 1989;10:285-95.
32. Wulfrank D, Schelstraete K, Small F, Charles F. Analogy between tumor uptake of technetium-99m-(V) dimercaptosuccinic acid (DMSA) and technetium-99m-MDP. Clin Nucl Med 1989;14:488-593.
33. Brandt-Mainz K, Muller SP, Gorges R. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490-6.
34. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66-71.
35. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004;11:786-94.
36. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
37. 18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003;88:637-41.
38. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging 2001;28(12):1751-7.
39. 111In-pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49(3):225-35.
40. 90Y-labeled somatostatin analogs. J Nucl Med 2005;Suppl 1:13S-17S.
41. 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006;26:703-7.
42. 90Y-DOTATOC. J Nucl Med 2005;46:1310-6.
43. 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004;19:65-71.